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2-agonists have questionable symptomatic eect in infants with acute bronchiolitis, whereas inhaled, nebulized
racemic adrenaline, commonly used in Norway, appears (clinically) to be eective. Limited lung function
observations during acute bronchiolitis exists, and less for assessing possible eects inhaled adrenaline.
In this preliminary study, tidal flow-volume loops were measured in 16 infants with acute bronchiolitis and seven
healthy controls (mean age 79 and 44 months, respectively), with repeated measurements 15 min after inhaled
nebulized racemic adrenaline (4 mg diluted in 2 ml saline) in nine bronchiolitis patients.
The ratio of time to reach peak tidal expiratory flow to total expiratory time tPTEF=tE was significantly reduced
in children with acute bronchiolitis (mean, 95% CI) (008, 005–010) compared to controls (031, 018–043), with
significant improvement after inhaled racemic adrenaline 019 (013–025), parallel with significant clinical
improvement.
Lung function tPTEF=tE was reduced in infants with acute bronchiolitis and improved significantly after inhaled
racemic adrenaline. Inhaled racemic adrenaline is potentially an important alternative for treating infants with
acute bronchiolitis.
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Medication available for the symptomatic treatment of
bronchiolitis in infants and very young children is often of
limited value. The main treatment of acute bronchial
obstruction (BO) in infants and toddlers with bronchiolitis
has been the administration of 2-agonists, theophyllines
and anti-cholinergic drugs.
The eect of 2-agonist administrated orally, by inhalation
or intravenously in infants with acute bronchiolitis is not
clear. Some studies have reported ecacy of nebulized
salbutamol (1–3), others found little or no eect in the
youngest children (4–8) and some even demonstrated a
paradoxical fall in oxygen saturation after salbutamol
administration in infants with bronchiolitis (4,7,9). In
Norway, inhaled nebulized racemic adrenaline has been
used as the main symptomatic treatment in young children
and infants with bronchiolitis for many years. EmpiricallyReceived 31 January 2000 and accepted in revised from 7 February
2000.
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of BO, and recent studies support this (10–13).
Measures of lung function to assess possible eects of
treatment in very young children are limited in general, and
specifically with treatment of acute respiratory diseases.
They are dicult to obtain during acute illness partly due to
distress of the baby, but also as sedation is generally
required for most types of measurements. However, in
sedated babies (during their first 3 days in hospital) with
bronchiolitis Sanchez et al. demonstrated a superior eect
upon pulmonary mechanics of nebulized epinephrine
compared to salbutamol (13). Henderson et al., on the
other hand, found no improvement in lung function by
nebulized epinephrine in asymptomatic infants with recur-
rent wheeze (14).
The present study was thus performed to assess by tidal
breathing parameters possible beneficial eect of inhaled
racemic adrenaline in babies with acute bronchiolitis.Methods
STUDY DESIGN
Nebulized racemic adrenaline was given openly to children
with acute bronchiolitis (as defined by Court) (15).
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the outpatient or inpatient clinic, and were included
after informed consent was given by their parents.
Exclusion criteria were patients with so severe bronchiolitis
that immediate treatment was required, a history of
recurrent wheeze or present or past history of atopic
dermatitis.
Measurements of tidal flow-volume (TFV) loops as well
as clinical assessment (10) were performed before, and
approximately 15 min after inhalation of racemic adrena-
line. All measurements were performed with the patients
awake, resting in their parents lap. The study was approved
by the regional ethics committee.
Additionally, seven of the patients eventually partici-
pated in another ongoing study [The ‘Environment and
Childhood Asthma’ Study (16)], where healthy controls
were included for lung function measurements. However,
these children did not receive racemic adrenaline, and only
baseline lung function measurements are used in the present
study for comparison.
SUBJECTS
Sixteen children (14 boys) with acute bronchiolitis, and
seven healthy controls (four girls) were included into the
present study. Characteristics of the children are given in
Table 1. Nasal swabs for virus detection was not performed
routinely, but respiratory syncytial virus (RSV) was
detected in three of the patients. One child only presented
with the second doctor-documented BO, but RSV was
detected from nasal swabs in this patient. Apart for one
child (who received racemic adrenaline 35 h prior to
measurement, at the local doctor’s surgery), none of the
children had received any - or -stimulating medication
on the day of testing prior to measurements. None of the
patients received any regular treatment. At the time of the
first measurement, all children with bronchiolitis had
moderately severe BO scored according to the scale of
Aas (17), where P0 denotes no obstruction to P6 denoting
severe, life-threatening BO.
LUNG FUNCTION AND CLINICAL
MEASUREMENTS
Lung function measurements were performed with the
SensorMedics 2600 system consisting of an IBM-PS2/50Z
(80286) computer with an outboard microprocessor
controlled (8085) analogue to digital conversion moduleTABLE 1. Age and weight in the 16 infants and toddlers with ac
Bronchiolitis
n  16
Con
n 
Age (months) 79 (59–99) 44 (2
Weight (kg) 89 (78–100) 71 (5(15 channels for conversion, multiplexed through three
14-bit D/As that perform digital oset, range and
conversion).
Flow was measured using a triple screen pneumotacho-
graf (4500 series, Hans Rudolph, Missouri, USA), with a
flow range of 0–30 l min71. Dierential pneumotach
pressure and mouth pressure was measured with Validyne
DP-250 transducers (commercial versions of the MP-45) at
+2 cm H2O and + 100 cm H2O, respectively. The pneu-
motach was fitted to a close-fitting mask covering nose and
mouth, with an air inflated cu of an appropriate size for
each infant. Integration of flow to volume was carried out
at a rate of 256 samples sec71, without any filtering of the
raw signal.
Tidal flow-volume (TFV) loops were stored in groups of
four, chosen as the most representative curves from tracings
of established tidal breathing. Real time analysis of the
recorded data was performed by the SensorMedics system,
and the reported data were derived from the mean of these
four loops, as was the case for the respiratory rate.
Measurements took approximately 1–5 min according to
the co-operation of the child.
Obstructive score based upon clinical examination was
assessed together with lung function measurements as soon
as practically possible after admission to the hospital,
before any medication was administered. Racemic adrena-
line (20 mg/ml71 02 ml diluted in 2 ml saline was then
administered to the patient by nebulization (Pari Standard).
STATISTICAL ANALYSES
Statistical analysis was carried out with the Number
Cruncher statistical system, and results are reported as
mean values with 95% CI (in parentheses) unless otherwise
stated. Dierences were tested by two-tailed Wilcoxon
signed rank tests for matched pairs. Dierences were
considered statistically significant with P-values 55%.
Results
The results of baseline TFV measurements are given in
Table 2, for all children with bronchiolitis, as well as
controls. Compared with controls, mean respiratory rate
tended to be higher (NS) (527 vs. 487 breaths min71,
respectively), and lung function parameters (such as
tPTEF=tE:008 vs. 031, respectively) significantly reduced
in children with acute bronchiolitis (Fig. 1).ute bronchiolitis and seven controls
trols
7
All subjects
n  23
P-value
8–60) 68 (53–84) 006
7–86) 835 (745–925) 002
TABLE 2. Lung function results in 16 children with bronchiolitis (B) and seven controls (C), before and 15 min after inhaled,
nebulized racemic adrenaline n  9
Repeated measurements n  9
Pre- Post- Bronchiolitis
n  16
Controls
n  7
P-value pre
vs: post/ B vs. C
Resp. rate 467 (394–540) 509 (426–592) 527 (457–597) 487 (312–662) 05/07
VE kg
71 (ml) 69 (57–81) 826 (70–95) 64 (55–72) 87 (79–96) 50001/004
tPTEF tE 008 (004–012) 019 (013–025) 008 (005–010) 031 (018–043) 0007/50.001
TEFTEF25/PTEF 046 (038–054) 063 (052–074) 045 (040–051) 070 (055–085) 004/0003
PTEF (ml se71) 1544 (1125–1962) 2110 (1447–2773) 1557 (1236–1877) 1475 (984–1966) 093/007
TEF50 1074 (775–1374) 1911 (1194–2627) 1006 (793–1219) 1310 (801–1819) 0003/032
P0-6 357 (267–447) 186 (087–285) 003/n.a.
n.a.: Not applicable.
FIG. 1. Tidal breathing lung function parameters in 16
infants with acute bronchiolitis and seven healthy
controls. (a) VE (expiratory volume kg
71) (P5004); (b)
tPTEF=tE (ratio of time to peak expiratory flow to total
expiratory time) (P500001).
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after inhalation treatment.
Repeated studies of TFV-loops after inhaled racemic
adrenaline were successful in nine children with acutebronchiolitis. The results of TFV measurements from
before to after inhaled, nebulized racemic adrenaline are
given in Table 2.
Tidal expiratory volume, tPTEF=tE (Fig. 2) and TEF25/
PTEF as well as mid-tidal expiratory flow (TEF50) all
improved significantly (P50004) from before to after
nebulized racemic adrenaline.
In one infant taking part in a double-blind placebo
controlled study (16) TFV loops were measured before any
treatment, 15 and 30 min after receiving inhalation of what
later was found to be placebo (with no clinical improve-
ment) and subsequently after inhaled racemic adrenaline
(openly given) (Fig. 3).
Discussion
Lung function, as measured by tidal flow volume loops was
significantly reduced in infants with acute bronchiolitis, and
improved significantly after inhaled, nebulized racemic
adrenaline. The significantly reduced tPTEF=tE and
TEF25/PTEF in infants with acute bronchiolitis are in
accordance with reduced lung function during acute
bronchiolitis in other studies (18–20). However, to our
knowledge, TFV parameters obtained in infants with acute
bronchiolitis have not previously been reported. One early
(21) and several recent studies by Morris et al. (22–24) in
adults, have demonstrated a clear association between
decreased time ratio (corresponding to tPTEF=tE ) and
airway obstruction. Diminished tidal time or volume ratios
have been reported even in asymptomatic subjects with
obstructive airways disease (due to recurrent wheeze or
asthma) (21,22,25–30), with a further reduction by provo-
cation with histamine or metacholine (21,25,26,30). Thus,
tPTEF=tE seems to be a reliable measure of airways
obstruction (23,31). The mean baseline tPTEF=tE (008) in
children with bronchiolitis reported in the present study
was lower than the values generally reported in asympto-
matic children (017–036) (25–28,30). This is to be
FIG. 2. Tidal breathing lung function parameters before
and after inhalation of nebulized racemic adrenaline, in
nine infants with acute bronchiolitis. (a) VE (expiratory
volume kg71) (P50001), (b) tPTEF=tE (ratio of time to
peak expiratory flow to total expiratory time) (P50001).
FIG. 3. Tidal flow volume loops in one 7-month-old boy
with acute bronchiolitis. The baseline curve (top left) was
measured during clinically moderately severe bronchial
obstruction (BO). Curves (top right) and (bottom left)
were measured after inhalation of what later was shown to
be placebo, with no change in clinical condition. Curve
(top right) was measured 15 min after openly given
nebulized racemic adrenaline, with a concomitant
attenuation of clinical BO.
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obstruction during measurements.
The significant improvements in tPTEF=tE and TEF25/
PTEF observed after inhalation of racemic adrenaline are
in accordance with several recent placebo controlled studies
in acute bronchiolitis, reporting improved clinical outcomes
(10–12), as well as lung mechanics (13) after nebulized
adrenaline. Improved tidal breathing parameters after
inhaled 2-agonists (salbutamol) have been demonstrated
in asymptomatic infants and young children with obstruc-
tive airways disease (other than bronchiolitis) (27,28,31,32).
However, one study found no eect on lung function
(partial forced expiratory flow volume loops and airway
conductance) of nebulized adrenaline in asymptomatic
infants younger than 18 months (14). In acute bronchiolitis,
it is possible that airway oedema plays an important role,
whereas the contribution of bronchial muscle constriction
may be relatively less important than is the case in acute
asthma. The combined ÿ and -receptor agonist racemic
adrenaline is believed to aect both vascular as well as
bronchial muscle, with a subsequent relief of BO. However,
in contrast to -receptor agonists, if the relief of BO by
racemic adrenaline is primarily due to the eects uponairway wall oedema, any major eect on the airways in the
absence of symptoms would be unlikely.
Although the present study was not placebo-controlled,
two of the patients (Fig. 3 demonstrating TFV loops in one)
took part in a double-blind, placebo-controlled study which
demonstrated a significant improvement in clinical outcome
after nebulized racemic adrenaline (10). However, it was
dicult to establish an appropriately quiet setting to obtain
TFV loops whilst attaching various equipment (including
blood pressure monitor) for the reported placebo-con-
trolled study, thus the present study focused upon
objectively measured TFV loops.
The present study is small, observational and with no
placebo group. However, even with successful repeated
measurements in only 9/17 children with acute bronchio-
litis, the dierence in tPTEF=tE was highly significant, with a
power of 93% to detect dierences (two-sided), with a
significance level of 005. The improved lung function
was paralleled by improvement in clinical parameters,
which is supported by previous reports of inhaled nebulised
adrenaline being superior to 2-agonist in relieving
symptoms of acute bronchiolitis (12,13). Furthermore,
previous reversibility studies from our laboratory have
demonstrated no (or paradoxical) eect upon TFV loops by
2-agonists in healthy infants, but significant improvement
in asymptomatic young children with obstructive airways
disease.
In conclusion, lung function measured by TFV loops was
reduced in awake infants with acute bronchiolitis, and
improved after inhaled nebulized racemic adrenaline.
Although the study was only preliminary, our results
INHALED NEBULIZED ADRENALINE FOR INFANTS WITH ACUTE BRONCHIOLITIS 713indicate that inhaled racemic adrenaline may be eective in
relieving symptoms in children with acute bronchiolitis who
in other countries are mainly treated with 2-agonists of
questionable eect (6,7,33,34). Further placebo-controlled
studies are warranted as these results, if solidly confirmed
may have a great impact upon general treatment guidelines
for this disease.
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